Tandem Diabetes Care Inc (FRA:TD5A)
€ 46.5 -0.61 (-1.29%) Market Cap: 3.09 Bil Enterprise Value: 3.10 Bil PE Ratio: 0 PB Ratio: 13.74 GF Score: 77/100

Tandem Diabetes Care Inc at Raymond James Institutional Investors Conference (Virtual) Transcript

Mar 01, 2021 / 08:00PM GMT
Release Date Price: €79.9 (+3.03%)
Jayson Tyler Bedford
Raymond James & Associates, Inc., Research Division - Senior Medical Supplies and Devices Analyst

Okay. Good morning -- or good afternoon. Welcome to the 42nd Annual Raymond James Institutional Investors Conference. I'm Jayson Bedford. I cover medical devices here at Raymond James.

It's really our privilege to have with us today the management team from Tandem Diabetes. With us today, we've got the company's CEO, John Sheridan; and CFO, Leigh Vosseller; and the company's Chief Administrative Officer, Susan Morrison.

So we're going to be doing mostly fireside chat, but I wanted to give John a quick opportunity to kind of set the stage, if you will.

John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director

Absolutely. Jayson, thanks very much for having us today. We're excited to be here. I just want to say that we are really excited about 2021. I think it's fair to look back and say that 2020 was a great year for us.

I think that the success of the company was largely driven by the appeal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot